A study on changes and clinical significance of blood glucose, blood lipid and inflammation in patients with ovarian cancer.

PURPOSE

To investigate the changes in blood glucose, blood lipid and inflammation in patients with ovarian cancer and their clinical significance.

METHODS

67 patients diagnosed with ovarian cancer and treated in our hospital from January 2018 to December 2018 constituted the observation group. Fifty healthy women in the corresponding time period were enrolled as the control group. The levels of blood glucose, blood lipid and inflammation were compared between the two groups, and then the changes in those levels in ovarian cancer patients in different clinical stages were analyzed.

RESULTS

The levels of fasting blood glucose and 2-h postprandial blood glucose of the observation group were significantly higher than those of the control group, and they were also significantly higher in patients in stage III-IV than those in stage I-II (p<0.05). In the observation group, the levels of total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) were lower than those in the control group. Compared with the patients in stage I-II, the patients in stage III-IV had remarkably lower levels of TC and HDL-C (p<0.05). The levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in the observation group were evidently higher than those in the control group, and they were markedly higher in patients in stage III-IV than those in stage I-II (p<0.05).

CONCLUSIONS

Both the metabolism disorders of blood lipid and blood glucose and inflammatory response are more obvious in ovarian cancer patients, indicating that these indicators have a place for early screening and clinical treatment of ovarian cancer.